Fig. 5: SNX16 promoted the recycling of EGFR in cardiomyocytes and the activation of the Src/EGFR signaling pathway.
From: SNX16 aggravates AngII-induced cardiac hypertrophy in mice via EGFR transactivation
A–C The colocalization of SNX16 and different endosome markers in H9c2 cells treated with EGF (1 μg/mL) or PBS for 15 min was determined by confocal microscopy analysis, and the cells were then stained with anti-SNX16 (green), anti-Rab5 (red), anti-Rab7 (red), and anti-Rab11 (red) antibodies and counterstained with DAPI (blue). Scale bar: 10 pixels. D The expression of EGFR and p-EGFR was detected by immunofluorescence analysis in H9c2 cells transfected with the SNX16-OE vector or vehicle for 48 h and then treated with or without wortmannin (100 nmol/L) for 30 min. The cells were then stained with anti-p-EGFR (red) or anti-EGFR (red) and counterstained with DAPI (blue). Scale bar: 20 μm. E Quantification of the mean fluorescence intensity of p-EGFR in (D). These p-values are from unpaired t-tests and one way-ANOVA, *p < 0.05. The data are presented as the means ± SEMs, and three independent experiments were performed.
